World-wide variation in HIV-1 phenotypic susceptibility in untreated individuals: biologically relevant values for resistance testing.
about
"Dynamic range" of inferred phenotypic HIV drug resistance values in clinical practicePASS-based approach to predict HIV-1 reverse transcriptase resistance.Novel method to assess antiretroviral target trough concentrations using in vitro susceptibility data.Determination of Phenotypic Resistance Cutoffs From Routine Clinical DataPrevalence of protease and reverse transcriptase drug resistance mutations over time in drug-naïve human immunodeficiency virus type 1-positive individuals in Rio de Janeiro, Brazil.Baseline susceptibility of primary human immunodeficiency virus type 1 to entry inhibitorsGeno2pheno: Estimating phenotypic drug resistance from HIV-1 genotypesClinical management of HIV drug resistance.In vitro hypersusceptibility of human immunodeficiency virus type 1 subtype C protease to lopinavir.Reduced maximal inhibition in phenotypic susceptibility assays indicates that viral strains resistant to the CCR5 antagonist maraviroc utilize inhibitor-bound receptor for entry.Characterization of HIV drug resistance mutations among patients failing first-line antiretroviral therapy from a tertiary referral center in Lusaka, ZambiaDrug resistance and antiretroviral drug development.Characterization of the Drug Resistance Profiles of Patients Infected with CRF07_BC Using Phenotypic Assay and Ultra-Deep Pyrosequencing.Significance of variation within HIV, EBV, and KSHV subtypes.Comparison of the precision and sensitivity of the Antivirogram and PhenoSense HIV drug susceptibility assaysCharacterization of a subtype D human immunodeficiency virus type 1 isolate that was obtained from an untreated individual and that is highly resistant to nonnucleoside reverse transcriptase inhibitors.Phenotypic and genotypic analyses to guide selection of reverse transcriptase inhibitors in second-line HIV therapy following extended virological failure in Uganda.Phenotypic susceptibilities to tenofovir in a large panel of clinically derived human immunodeficiency virus type 1 isolates.Use of tissue culture cell lines to evaluate HIV antiviral resistance.Natural variation of drug susceptibility in wild-type human immunodeficiency virus type 1In Vitro Activity of Simeprevir against Hepatitis C Virus Genotype 1 Clinical Isolates and Its Correlation with NS3 Sequence and Site-Directed Mutants.Nucleotide and amino acid polymorphisms at drug resistance sites in non-B-subtype variants of human immunodeficiency virus type 1.Hypersusceptibility to substrate analogs conferred by mutations in human immunodeficiency virus type 1 reverse transcriptase.Baseline resistance of primary human immunodeficiency virus type 1 strains to the CXCR4 inhibitor AMD3100.Novel method for simultaneous quantification of phenotypic resistance to maturation, protease, reverse transcriptase, and integrase HIV inhibitors based on 3'Gag(p2/p7/p1/p6)/PR/RT/INT-recombinant viruses: a useful tool in the multitarget era of antStructural analysis of an HIV-1 protease I47A mutant resistant to the protease inhibitor lopinavir.Drug-resistance mutations in antiretroviral-naïve patients with established HIV-1 infection in Mexico.Prevalence of nonnucleoside reverse transcriptase inhibitor (NNRTI) resistance-associated mutations and polymorphisms in NNRTI-naïve HIV-infected patients.
P2860
Q28477270-30DCA3A2-E540-48A9-ACE4-C7A55177C4BCQ30490600-B4BD9CA6-0866-471E-99DE-83DF950864B4Q30564087-1ED6D00E-3595-4264-B67C-29A8DC453AC6Q31139379-F6E27F67-C3A6-4FD4-B344-241AE13F001DQ34112169-37A5CF08-7AC4-46F9-A729-5DAA9232BC50Q34465544-2505E03D-57BA-4778-A439-189940FB82AFQ35208107-010AE17C-2CF5-4B84-9C0F-FB1D10CA2988Q35261045-D5EC0FB0-1C25-46A7-A960-C85C0A7DEB8EQ35685268-C2A86C4A-3BB3-42D0-A5C4-45FC6B1B5B8DQ35784750-64C10C28-5F9D-4019-8E39-CD6BC1334FAEQ35810923-5F54EAF9-C78F-4D3F-A5A9-C80322488EECQ36104277-A0CDFD21-FE3A-4E91-B562-540CA0C32203Q36255602-9C86A349-4DCB-4B0C-A409-DB84BFFDC682Q36575166-759561AA-383A-4DEF-9787-40FCB7E518D1Q36899994-8C1E21F0-BBF7-4004-8901-584120D7057EQ37730522-51E486C0-E488-4AA8-8643-011AF9E15155Q38848190-906AB319-C14E-49E7-97D1-3F72917DD74EQ39651462-DB835530-977C-4462-BAAD-77D5D12AE2A1Q39955277-9A1484E1-8B56-4C5C-91DF-4EE001E3EE55Q40469287-E4EDB31A-A484-49D3-BFBC-6A861A25664DQ40988716-9025FF3F-6451-4E4D-BD85-9D548E813176Q41269046-91CECF33-45F5-4528-B481-5C8F48364828Q41495257-EF043A83-6F58-4665-98E0-8A9F46497E90Q41857872-C465FE8D-A107-4192-B61E-B6DB3C1904BEQ42148219-C2B6D72C-27BE-4A53-AF2A-8778F80BE20DQ43057951-64307D50-B956-404C-A760-BEE2B3C4552EQ46789888-7A4614B3-366E-417D-94CE-F73701DC686FQ53981013-0944469E-41E6-42CD-8847-1EB32E5D432C
P2860
World-wide variation in HIV-1 phenotypic susceptibility in untreated individuals: biologically relevant values for resistance testing.
description
2001 nî lūn-bûn
@nan
2001年の論文
@ja
2001年学术文章
@wuu
2001年学术文章
@zh-cn
2001年学术文章
@zh-hans
2001年学术文章
@zh-my
2001年学术文章
@zh-sg
2001年學術文章
@yue
2001年學術文章
@zh
2001年學術文章
@zh-hant
name
World-wide variation in HIV-1 ...... values for resistance testing.
@en
World-wide variation in HIV-1 ...... values for resistance testing.
@nl
type
label
World-wide variation in HIV-1 ...... values for resistance testing.
@en
World-wide variation in HIV-1 ...... values for resistance testing.
@nl
prefLabel
World-wide variation in HIV-1 ...... values for resistance testing.
@en
World-wide variation in HIV-1 ...... values for resistance testing.
@nl
P2093
P1433
P1476
World-wide variation in HIV-1 ...... values for resistance testing.
@en
P2093
Harrigan PR
Montaner JS
Verbiest W
P304
P356
10.1097/00002030-200109070-00010
P407
P577
2001-09-01T00:00:00Z